Your Name: Manuscript Title:			9/4/2022		
			Aonan Zhao Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer's disease		
Mai	nuscript Number (if k	(nown):	158708-JCI-CM ED -RV-3	_	
con affe indi The epic	tent of your manuscr cted by the content of cate a bias. If you are author's relationship	ipt. "Rel of the ma e in douk os/activit nsion, yo	e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so. es/interests should be defined broadly. For example, if your manuscript pertains to the u should declare all relationships with manufacturers of antihypertensive medication, even if in the manuscript.		
	em #1 below, report ne for disclosure is th		ort for the work reported in this manuscript wit 5 months.	chout time limit. For all other items, the time	
			all entities with whom you have this nship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item	medic	None al writing analysis	provision of study materials Click the tab key to add additional rows.	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	medic	al writing analysis	provision of study materials Click the tab key to add additional rows.	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	medic data	al writing	provision of study materials Click the tab key to add additional rows.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None ■	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ⊠	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:			9/4/2022			
Your Name: Manuscript Title:			Yang Jiao			
			Soluble TREM2 levels associate with conversi Alzheimer's disease	Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer's disease		
Ma	nuscript Number (if k	(nown):	158708-JCI-CM ED -RV-3			
con affe indi	tent of your manuscrected by the content of icate a bias. If you are author's relationship	ipt. "Re of the m e in dou os/activi	lated" means any relation with for-profit or not anuscript. Disclosure represents a commitment of about whether to list a relationship/activity/ities/interests should be defined broadly. For ex	e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so. es/interests should be defined broadly. For example, if your manuscript pertains to the		
-	t medication is not m	-	ou should declare all relationships with manufact d in the manuscript.	cturers of antimypertensive medication, even in		
	tem #1 below, report ne for disclosure is th		ort for the work reported in this manuscript wit 6 months.	hout time limit. For all other items, the time		
			all entities with whom you have this nship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
					_	
			Time frame: Since the initial planning	of the work		
1	All support for the present manuscript (e.g.,		Time frame: Since the initial planning None cal writing	of the work		
1	present		None cal writing	of the work Click the tab key to add additional rows.		
1	present manuscript (e.g., funding, provision		None cal writing			
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing		None cal writing			
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for		None cal writing	Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	medi	None cal writing	Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	medi	None cal writing Time frame: past 36 month	Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not	medi	None cal writing Time frame: past 36 month	Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	medi	None cal writing Time frame: past 36 month	Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above). Royalties or	medi	None cal writing Time frame: past 36 month None	Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above). Royalties or	medi	None cal writing Time frame: past 36 month None	Click the tab key to add additional rows.		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None ■	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ⊠	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Your Name: Manuscript Title:			9/4/2022			
			Guanyu Ye			
			Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer's disease			
Ma	nuscript Number (if k	nown):	158708-JCI-CM ED -RV-3			
con affe ind The epic	etent of your manuscrected by the content of icate a bias. If you are author's relationship demiology of hyperte	ipt. "Rel of the ma e in douk os/activit nsion, yo	e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so. es/interests should be defined broadly. For example, if your manuscript pertains to the u should declare all relationships with manufacturers of antihypertensive medication, even if			
tha	t medication is not m	entioned	l in the manuscript.			
	tem #1 below, report me for disclosure is th		ort for the work reported in this manuscript wi 5 months.	thout time limit. For all other items, the time		
			all entities with whom you have this nship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the		1			
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		ion of study materials	Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for					
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	provis	ion of study materials			
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	provis	ion of study materials Time frame: past 36 monti			
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	provis	ion of study materials Time frame: past 36 monti			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None ■	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ⊠	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:			9/4/2022			
Your Name: Manuscript Title:			Wenyan Kang			
			Soluble TREM2 levels associate with conversion Alzheimer's disease	on from mild cognitive impairment to		
Mai	nuscript Number (if k	(nown):	158708-JCI-CM ED -RV-3			
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub." The author's relationships/activities.			e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so. es/interests should be defined broadly. For example, if your manuscript pertains to the u should declare all relationships with manufacturers of antihypertensive medication, even if			
In it	em #1 below, report ne for disclosure is th	all suppo	rt for the work reported in this manuscript wit	hout time limit. For all other items, the time		
			Il entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		on of study materials	Click the tab key to add additional rows.		
			Time frame: past 36 months	s		
2	Grants or contracts from any entity (if not indicated in item #1 above).	× N	lone			
3						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None ■	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ⊠	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Your Name: Manuscript Title:			9/4/2022 Tan Lan				
			Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer's disease				
Mar	nuscript Number (if k	nown):	158708-JCI-CM ED -RV-3				
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub." The author's relationships/activitic epidemiology of hypertension, you that medication is not mentioned.			nanuscript. Disclosure represents a commitment of about whether to list a relationship/activity/ ities/interests should be defined broadly. For expousing the should declare all relationships with manufated in the manuscript.	t-for-profit third parties whose interests may be to transparency and does not necessarily interest, it is preferable that you do so. cample, if your manuscript pertains to the cturers of antihypertensive medication, even if			
			all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
			Time frame: Since the initial planning	of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	prov	None ision of study materials	Click the tab key to add additional rows.			
			Time frame: past 36 month	ns			
2	Grants or contracts from any entity (if not indicated in item #1 above).		None				
3	Royalties or licenses		None				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None ■	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	se place an "X" next	to the	e following statement to indicate your agreemen	ıt:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: Your Name: Manuscript Title:		9/4/2022	9/4/2022				
		YuanyuanLi	YuanyuanLi				
		Soluble TREM2 levels associate with conve Alzheimer's disease	sion from mild cognitive impairment to				
Ma	nuscript Number (if kı	nown):158708-JCI-CMED-RV-3					
con affe	tent of your manuscri ected by the content o	rency, we ask you to disclose all relationships/activiti pt. "Related" means any relation with for-profit or n of the manuscript. Disclosure represents a commitme in doubt about whether to list a relationship/activity	ot-for-profit third parties whose interests may be nt to transparency and does not necessarily				
epi	demiology of hyperten	s/activities/interests should be defined broadly. For nsion, you should declare all relationships with manu entioned in the manuscript.					
		all support for the work reported in this manuscript v	rithout time limit. For all other items, the time				
frai	THE TOT GISCIOSUTE IS THE	e past 36 months.					
frai	ne for disclosure is the	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)				
frai	ne for disclosure is the	Name all entities with whom you have this	made to you or to your institution)				
frai	All support for the	Name all entities with whom you have this relationship or indicate none (add rows as needed)	made to you or to your institution)				
	All support for the present manuscript (e.g.,	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning	made to you or to your institution)				
	All support for the present manuscript (e.g., funding, provision of study materials,	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning None	made to you or to your institution) g of the work				
	All support for the present manuscript (e.g., funding, provision	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning None	made to you or to your institution) g of the work funding				
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning None	made to you or to your institution) g of the work funding Click the tab key to add additional rows.				

#1 above).

Royalties or

licenses

None

3

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

Your Name: Manuscript Title:			9/4/2022				
			Yulei Deng				
			Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer's disease				
Ma	nuscript Number (if k	nown):	158708-JCI-CM ED -RV-3				
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the maindicate a bias. If you are in doub! The author's relationships/activities.			e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so. es/interests should be defined broadly. For example, if your manuscript pertains to the u should declare all relationships with manufacturers of antihypertensive medication, even if				
tha	t medication is not m	entioned	l in the manuscript.				
	em #1 below, report ne for disclosure is th		ort for the work reported in this manuscript wit 5 months.	hout time limit. For all other items, the time			
			all entities with whom you have this as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
			Time frame: Since the initial planning	of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None al writing	of the work Click the tab key to add additional rows.			
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for		None al writing	Click the tab key to add additional rows.			
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	medic	None al writing	Click the tab key to add additional rows.			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	se place an "X" next	to the	e following statement to indicate your agreemen	ıt:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:			9/4/2022			
Your Name:			Jun Liu			
Manuscript Title:			Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer's disease			
Ма	nuscript Number (if k	(nown):	158708-JCI-CM ED -RV-3			
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub." The author's relationships/activiti			e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily about whether to list a relationship/activity/interest, it is preferable that you do so. es/interests should be defined broadly. For example, if your manuscript pertains to the u should declare all relationships with manufacturers of antihypertensive medication, even if			
In it	t medication is not m em #1 below, report ne for disclosure is th	all supp	ort for the work reported in this manuscript wit	hout time limit. For all other items, the time		
			all entities with whom you have this nship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	medi	None cal writing ned the study	Funding Click the tab key to add additional rows.		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	medi	None cal writing ned the study	Funding Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	medi desig	None cal writing ned the study	Funding Click the tab key to add additional rows.		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	se place an "X" next	to the	e following statement to indicate your agreemen	ıt:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.